Institutional investors purchased a net $1.7 million shares of OPK during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 14.17% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
| Other institutional | 8.27% |
| Individual stakeholders | 52.88% |
| Mutual fund holders | 5.90% |